Loading clinical trials...
Loading clinical trials...
A Phase 1 Dose-Escalation Study To Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed By an Open-Label Evaluation of LX214 Ophthalmic Solution in Patients With Keratoconjunctivitis Sicca
Conditions
Interventions
voclosporin ophthalmic solution
Locations
1
United States
Product Investigations
Conshohocken, Pennsylvania, United States
Start Date
February 1, 2009
Primary Completion Date
March 1, 2009
Completion Date
April 1, 2009
Last Updated
June 22, 2012
NCT03925727
NCT03418259
NCT02688556
NCT02845674
NCT01797822
NCT02665234
Lead Sponsor
Lux Biosciences, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions